eccogene glp 1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases eccogene glp-1 Obesity plus': What's
Pay in 4 interest-free payments of $6.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1


-agonists-market-key-insight.png)





/assets/images/provider/photos/2775905.jpeg)

















